# The Capital Partnership

> The Capital Partnership is a VC fund backing Health Care and Medical Device. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 24
- Last investment: Mar 2025
- Lead investor: 46%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/the-capital-partnership
- X (Twitter): https://twitter.com/tcpam
- Website: http://tcpam.com/
- Facebook: https://www.facebook.com/The-Capital-Partnership-944482715672162/

The Capital Partnership is an independent asset manager providing institutional and private investors with a comprehensive range of asset management and wealth preservation services. Established in 1998, The Capital Partnership was created to provide sophisticated investment services to the families of its founding partners. The success of thefirm's approach allowed it to expand its services and capabilities and offer them to institutions and other large families in EMEA with similar asset management requirements.With offices in London and Dubai, The Capital Partnership is the advisor to a number of leading global institutions and family groups - helping them to address a range of challenges to the growth and preservation of their assets. The Capital Partnership Group Limited, the group's ultimate holding company is incorporated in the Dubai International Financial Centre (DIFC). The Capital Partnership (UK) Limited, the group's UK operating subsidiary is Authorised and Regulated by the Financial Conduct Authority.

## Contacts

5 contacts available for The Capital Partnership. Shizune tracks 7 team members at The Capital Partnership. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-capital-partnership?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 38% |
| Medical Device | 9 | 38% |
| Medical | 8 | 33% |
| Wellness | 2 | 8% |
| Apps | 1 | 4% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 29% |
| Series B | 7 | 29% |
| Series C | 3 | 13% |
| Series D | 2 | 8% |
| Series E | 2 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 42% |
| United Kingdom | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Abdelaziz El Gendy | Chief Executive Office | 0 | https://shizune.co/investors/profile/abdelaziz-el-gendy |
| Ahmed Ben Halim | Founding Partner | 0 | https://shizune.co/investors/profile/ahmed-ben-halim |
| Ali Ojjeh | Founding Partner & CEO | 1 | https://shizune.co/investors/profile/ali-ojjeh |
| Amy Harvey | General Counsel | 0 | https://shizune.co/investors/profile/amy-harvey |
| Tim Savage | Chief Financial Officer | 0 | https://shizune.co/investors/profile/tim-savage-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Supira Medical | Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M | Series E | Mar 26, 2025 |  |
| Laza Medical | Laza Medical is a privately held startup focused on producing a high-quality AI-powered robotic imaging solution for cardiovascular treatments. | $36M | Series A | Dec 12, 2023 |  |
| Supira Medical | Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M | Series D | Nov 21, 2023 |  |
| Akura Medical | Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $35M | Series B | Oct 03, 2023 |  |
| Myra Vision | Myra Vision designs a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma. It is a privately held portfolio company of Shifamed LLC. The company accelerates its development of the first-of-its-kind treatment for patients with moderate to severe glaucoma through its latest funding. | $25M | Series B | Jun 26, 2023 |  |
| Tioga Cardiovascular | Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $30M | Series C | Feb 09, 2023 |  |
| Atia Vision | Atia Medical is a medical device company focusing on advancing eye care through the innovation of ophthalmic devices, diagnostics, and pharmaceuticals. The company is focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer healthierlives. They improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens.Atia Vision modular intraocular lens technology features an accommodating base responsive to the ciliary muscles, simulating the natural mechanism of the eye and fixed lens element that allows for subsequent refractive correction. The company's unique technology enables natural accommodation, utilizing the ciliary muscles of the eye and providing for subsequent refractive correction, to restore the full range of functional vision for cataract patients.Atria Vision was founded in 2012 and is headquartered in Campbell, California, United States. | $42M | Series E | Aug 02, 2022 |  |
| Adona Medical | Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $37.5M | Series B | Apr 29, 2022 |  |
| Supira Medical | Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $30M | Series C | Feb 28, 2022 |  |
| Mindstep | Our mission is to make 1 million brains healthier by lowering the nation’s dementia risk. Founded by medics, Mindstep embodies core NHS-values: accessibility, empathy, and scientific rigour, to deliver the best-in-class care. Proud to be nerdy, and coded with compassion. | $3.4M | Seed | Jan 15, 2022 |  |

10 of 24 investments shown.

## Co-investors
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 15 deals together
- [AMED Ventures](https://shizune.co/investors/profile/amed-ventures) — VC Fund, 9 deals together
- [Shifamed](https://shizune.co/investors/profile/shifamed) — VC Fund, 8 deals together
- [PA MedTech VC Fund](https://shizune.co/investors/profile/pa-medtech-vc-fund) — VC Fund, 6 deals together
- [415 Capital](https://shizune.co/investors/profile/415-capital-management) — VC Fund, 4 deals together
- [Unorthodox Ventures](https://shizune.co/investors/profile/unorthodox-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does The Capital Partnership invest in?

The Capital Partnership invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact The Capital Partnership?

Public channels for The Capital Partnership include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at The Capital Partnership?

The team at The Capital Partnership includes Abdelaziz El Gendy (Chief Executive Office), Ahmed Ben Halim (Founding Partner) and Ali Ojjeh (Founding Partner & CEO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co